Insider Trading Alert - CRL, TMO And CVLT Traded By Insiders
Yesterday, Nov. 3, 2015, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $9.84 to $10,914,626.52.
Highlighted Stocks Traded by Insiders:
Charles River Laboratories International In (CRL) - FREE Research Report
Chubb Stephen D, who is Director at Charles River Laboratories International In, sold 2,000 shares at $66.57 on Nov. 3, 2015. Following this transaction, the Director owned 13,504 shares meaning that the stake was reduced by 12.9% with the 2,000-share transaction.
The shares most recently traded at $71.11, up $4.54, or 6.38% since the insider transaction. Historical insider transactions for Charles River Laboratories International In go as follows:
- 4-Week # shares sold: 4,720
- 12-Week # shares sold: 4,720
- 24-Week # shares sold: 4,720
The average volume for Charles River Laboratories International In has been 433,400 shares per day over the past 30 days. Charles River Laboratories International In has a market cap of $3.2 billion and is part of the health care sector and health services industry. Shares are up 7.67% year-to-date as of the close of trading on Tuesday.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and preclinical development services worldwide. The company has a P/E ratio of 23.4. Currently, there are 6 analysts who rate Charles River Laboratories International In a buy, 1 analyst rates it a sell, and 6 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on CRL - FREE
rates Charles River Laboratories International In as a
. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full
Charles River Laboratories International In Ratings Report
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Thermo Fisher Scientific (TMO) - FREE Research Report
Manzi Jim P, who is Director at Thermo Fisher Scientific, sold 3,050 shares at $133.49 on Nov. 3, 2015. Following this transaction, the Director owned 38,870 shares meaning that the stake was reduced by 7.28% with the 3,050-share transaction.
The shares most recently traded at $134.18, up $0.69, or 0.51% since the insider transaction. Historical insider transactions for Thermo Fisher Scientific go as follows:
- 4-Week # shares sold: 25,000
- 12-Week # shares sold: 29,557
- 24-Week # shares sold: 44,557
The average volume for Thermo Fisher Scientific has been 2.0 million shares per day over the past 30 days. Thermo Fisher Scientific has a market cap of $53.7 billion and is part of the health care sector and health services industry. Shares are up 7.16% year-to-date as of the close of trading on Tuesday.
Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The stock currently has a dividend yield of 0.45%. The company has a P/E ratio of 27.4. Currently, there are 15 analysts who rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on TMO - FREE
rates Thermo Fisher Scientific as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, reasonable valuation levels, good cash flow from operations and growth in earnings per share. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full
Thermo Fisher Scientific Ratings Report
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
CommVault Systems (CVLT) - FREE Research Report
Merrill Gary, who is Chief Accounting Officer at CommVault Systems, sold 2,307 shares at $40.46 on Nov. 3, 2015. Following this transaction, the Chief Accounting Officer owned 30,499 shares meaning that the stake was reduced by 7.03% with the 2,307-share transaction.
The shares most recently traded at $40.89, up $0.43, or 1.05% since the insider transaction. Historical insider transactions for CommVault Systems go as follows:
- 4-Week # shares bought: 2,000
- 4-Week # shares sold: 4,300
- 12-Week # shares bought: 2,000
- 12-Week # shares sold: 4,300
- 24-Week # shares bought: 2,000
- 24-Week # shares sold: 4,300
The average volume for CommVault Systems has been 556,300 shares per day over the past 30 days. CommVault Systems has a market cap of $1.8 billion and is part of the technology sector and computer software & services industry. Shares are down 20.91% year-to-date as of the close of trading on Tuesday.
CommVault Systems, Inc., together with its subsidiaries, provides data and information management software applications and related services primarily in North America, Europe, Australia, and Asia. The company has a P/E ratio of 92.0. Currently, there are 5 analysts who rate CommVault Systems a buy, no analysts rate it a sell, and 5 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on CVLT - FREE
rates CommVault Systems as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full
CommVault Systems Ratings Report
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.